Search

Your search keyword '"Graff-Radford, Neill R"' showing total 2,124 results

Search Constraints

Start Over You searched for: Author "Graff-Radford, Neill R" Remove constraint Author: "Graff-Radford, Neill R"
2,124 results on '"Graff-Radford, Neill R"'

Search Results

1. Investigation of the genetic aetiology of Lewy body diseases with and without dementia

3. Network Connectivity Alterations across the MAPT Mutation Clinical Spectrum

4. Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies

5. A systematic review of progranulin concentrations in biofluids in over 7,000 people—assessing the pathogenicity of GRN mutations and other influencing factors

6. HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases

7. Abundant transcriptomic alterations in the human cerebellum of patients with a C9orf72 repeat expansion

8. Role of GBA variants in Lewy body disease neuropathology

9. LATE-NC risk alleles (in TMEM106B, GRN, and ABCC9 genes) among persons with African ancestry.

10. Differences in Motor Features of C9orf72, MAPT, or GRN Variant Carriers With Familial Frontotemporal Lobar Degeneration.

11. The contribution of behavioral features to caregiver burden in FTLD spectrum disorders

12. CSF proteomics identifies early changes in autosomal dominant Alzheimer’s disease

13. γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)

14. Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups.

15. Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice

16. Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia

17. TDP-43-regulated cryptic RNAs accumulate in Alzheimer’s disease brains

18. Sex difference in evolution of cognitive decline: studies on mouse model and the Dominantly Inherited Alzheimer Network cohort

19. Proposed research criteria for prodromal behavioural variant frontotemporal dementia

20. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders

21. TDP-43 represses cryptic exon inclusion in the FTD–ALS gene UNC13A

22. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer’s disease

23. MAPT H2 haplotype and risk of Pick's disease in the Pick's disease International Consortium: a genetic association study

24. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study

25. Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimaging

26. Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium

27. The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology

28. Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood

29. Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration

30. Presymptomatic and symptomatic MAPT mutation carriers feature functional connectivity alterations

31. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis

32. Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia.

33. Circular-SWAT for deep learning based diagnostic classification of Alzheimer's disease: application to metabolome data

34. Brain volumetric deficits in MAPT mutation carriers: a multisite study

35. Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease

36. Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol

37. Plasma neurofilament light chain levels reflect caregiver burden and social cognition measures in familial frontotemporal lobar degeneration (FTLD)

38. Genome-wide structural variant analysis identifies risk loci for non-Alzheimer’s dementias

39. Clinical and pathologic features of cognitive-predominant corticobasal degeneration

40. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

41. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.

42. Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration.

43. Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood

44. Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers

45. An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations

46. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

47. Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD

48. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

49. Rates of lobar atrophy in asymptomatic MAPT mutation carriers.

50. Covariance-based vs. correlation-based functional connectivity dissociates healthy aging from Alzheimer disease

Catalog

Books, media, physical & digital resources